Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted Extracellular Vesicle Gene Therapy for Modulating Alpha-Synuclein Expression in Gut and Spinal Cord

13 Apr 2023

Abstract excerpt

The development of effective disease-modifying therapies to halt Parkinson's disease (PD) progression is required. In a subtype of PD patients, alpha-synuclein pathology may start in the enteric nervous system (ENS) or autonomic peripheral nervous system. Consequently, strategies to decrease the expression of alpha-synuclein in the ENS will be an approach to prevent PD progression at pre-clinical stages in these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular vesicles in disease
Share to Nerve injury and regeneration
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37111717
DOI: 10.3390/pharmaceutics15041230

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted Extracellular Vesicle Gene Therapy for Modulating Alpha-Synuclein Expression in Gut and Spinal CordPMID 37111717Read ↗

Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice.Semantic proximity Read ↗

Modeling the pathological brain-gut axis in Parkinson’s disease using human iPSC derived brain-intestinal assembloidsSemantic proximity Read ↗

Therapeutic effects of engineered exosome-based miR-25 and miR-181a treatment in spinocerebellar ataxia type 3 mice by silencing ATXN3Semantic proximity Read ↗

The Parkinson's disease‐associated protein α‐synuclein inhibits hepatoma by exosome deliverySemantic proximity Read ↗

Exosomes in Parkinson diseaseSemantic proximity Read ↗

Robust nuclease-dead S. aureus dCas9-mediated alpha-synuclein knockdown in substantia nigra in a humanized mouse model of Parkinson’s diseaseSemantic proximity Read ↗

Erythrocytic α‐Synuclein and the Gut Microbiome: Kindling of the Gut‐Brain Axis in Parkinson's DiseaseSemantic proximity Read ↗

Gene Therapy to Modulate Alpha-Synuclein in SynucleinopathiesSemantic proximity Read ↗

Parkinson mice show functional and molecular changes in the gut long before motoric disease onsetSemantic proximity Read ↗

Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes.Semantic proximity Read ↗

Human α-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapySemantic proximity Read ↗

CRISPR/Cas9-mediated gene editing induces neurological recovery in an A53T-SNCA overexpression rat model of Parkinson’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.